● Recruiting

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

Condition: Alopecia Areata · Sponsor: NEXTGEN Bioscience

PhasePhase 2

Planned participants73

Who can joinAll sexes, 19 Years to 65 Years

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

This description comes directly from the study's public registry record.

Talk to the study team

Heesun Kim · 82-31-606-3220 · flower@nextgenbio.co.kr

YangHye Park · yhpark@nextgenbio.co.kr

Always discuss trial participation with your own doctor first.

Locations (2)

Seoul National University Hospital.	Seoul, South Korea	Recruiting
Kyung Hee University Hospital at Gangdong	Seoul, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06104839